Abstract
The generic industry is a fast evolving market; with significant lucrative
opportunities. The generic market is structurally set to experience high
growth potential. That wave is partly driven by cost-containment in several
national healthcare sectors and partly by the need for governments to promote
the use of generic products over high-priced originator products without
compromising quality.
In 2006, the global generics market attained strong revenues of approximately
$65bn, up by 12% in comparison with $58bn in 2005. However, during the same
period, the Top Ten leading generic suppliers generated total revenues of
$27.9bn, up by a growth rate of 34%. The Top Five Companies within that sector
experienced significant revenues, with market growth largely driven by
significant commercial activities, key Mergers and Acquisition (M&A) and
launch of new product in the leading markets.
In light, of the significant number of proprietary branded pharmaceuticals
approaching patent expiration in the near-term, visiongain predicts that the
generic market is set to experience further market expansion during the
forecast period. Visiongain also predicts that by 2023, the Top Ten leading
generic suppliers will experience CAGR of 7%. That significant CAGR, will be
driven by generic versions of leading blockbuster drugs presently estimated at
$100bn, nearing patent expiration during 2008-2012.
Prominently, amongst the products with looming patent expirations are drugs
such as:
- Pfizer' s Lipitor
- AstraZeneca' s Nexium
- Bristol Myers Squib' s Plavix
- Pfizer' s Norvasc
- Lilly' s Zyprexa
- Janssen' s Risperdal
- Wyeth' s Effexor
In 2007, a total of 14 drugs came of patent in the US market. In 2008, a total
of 14 drugs are expected to lose patent protection in the US market. In 2009,
five drugs are predicted to becoming off-patent in the US market. On the 24 of
March 2010, the world' s highest selling drug, Pfizer' s Liptor will come
off-patent in the US. In the EU market, UCB' s Keppra and four other medicines
are expected to lose patent protection. In 2011, 10 major drugs in the US
market will also become exposed to generic competition. An estimated 11 drugs
will experience generic competition in the EU market during the same year.
Significant among these drugs will be Lipitor and Zyprexa.
Moreover, the generic market is projected to further expand through the
growing uptake of biogeneric/ biosimilar products. In 2006, biological drugs,
the products of biotechnology generated total revenues of $40bn. The US market
alone, accounted for a significant proportion of total worldwide sales.
Presently, in the EU, the growing popularity of these products are gaining
newer heights, with managed care organisations (MCOs), healthcare providers
and payers amongst others increasingly requesting these medicines as a
significant cost-saving strategy. However, by 2010, an estimated 24 biologic
drugs will near patent expiration opening up the market for generic
possibilities.
Visiongain' s market analysis forecast a-to- be lucrative era during the
mid-term of our forecast where we believe, the Top Ten generic suppliers will
see strong sales growth leveraged through licensing of new products.
With Top Ten company-by-company forecast focus on regions:
- Asia
- Europe
- Actavis (Finland)
- Merck KGaA (Germany)
- Ratiopharm (Germany)
- Sandoz (Switzerland)
- Stada (Germany)
- North America
- Apotex (Canada)
- Barr (US)
- Mylan (US)
- Watson (US)
This report includes detailed five-year forecasts over the period 2007-2012,
and NOW features 10 and 15-year forecasts to help you understand the
medium-term prospects for these markets.
Why You Must Buy This Report:
This report features in-depth primary research, tables, graphs and charts,
news, insights, the past and present developments in Market. This report will
provide you with the complete understanding of operations of Top Ten companies
that has driven their corporate growth in recent times. In addition, the
report sheds significant emphasis on key strategies that will drive
year-on-year sales growth of their leading products. Despite the lucrative
opportunities presented to the leading companies through patent expirations,
the visiongain reports analyses the key battles that the leading Top Ten
generic companies will face during the same period.
This visiongain report is the single tool to equip you with the latest trends
in all regional markets and why all (stakeholders) are opting for cheaper
generic medicine, that are equally potent as their originator versions.
Visiongain recommends this astute report to the major players in the field as
it will arm you with the major legal challenges that leading companies face to
date. The report, will also inform you on how the Top Ten generic companies
are positioning themselves in facing the rising inherent cost of R&D
expenditure especially on difficult-to-manufacture biogeneric/ biosimilars. In
addition, the reports present a 360 degrees overview of requirements set by
major regulatory authorities for larger evidence of clinical data before any
authorisation.
When you buy this report, you will also get an understanding, through our
overview; of how present changes in Governmental Pharmaceutical Policies with
respect to cost-cutting coupled with major hurdles by that the Top Ten generic
suppliers will have to overcome in the growing presence of price erosion
/sensitivity in key and emerging markets. The Top Ten Generic League Market
Analysis & Forecasts 2007-2023 report is a must buy, because it presents
in-depth and unbiased financial analysis for the near-term, medium-term and
the long-term, market dynamics.
When you buy the Visiongain 2008 Top Ten Generic League report, you will be
buying current and vital information on the vast array of commercial
opportunities marked for potential success in the long-term treatment of the
generic market.
Unique benefits to you when you order this report:
- - Primary research throughout. You will not find this information anywhere
else
- - Report stored in your reading room for ever
- - Full searchable report when you buy the company or corporate editions
- - Copies can be printed off for offline reading
- - Packed with charts, analysis, figures, graphs and tables
What questions does the report answer?
- Who are the generic market leaders?
- Which regions dominate the generic market?
- Which of the Top Ten companies conducted key M&As to bolster product
pipeline?
- Have the M&As been successful in expanding product range?
- Is the cost of branded medicines justifiable by Big Pharma?
- How will the Top Ten account for future revenues?
- Will the Top Ten continue to experience market share expansion?
- How will the Top Ten overcome the legal battles?
- Are the legal battles really worth the cost of the generic medicines?
- What direction is Biogenerics marketing taking?
- Will the EU regulatory bodies narrow the generic gap between the US?
- Will the Top Ten themselves be acquired under mounting pressure of strong
market competitions?
- Will the rising cost of R&D, deter the Top Ten from investing?
- Are the voices of managed care organisations (MCOs), healthcare providers
and payers driving down sales of Big Pharm' s blockbusters?
- Is the EU a "nice-to-operate-in" or a "must-operate-in" market for the Top
Ten?
| 
View Cart
